INDIVUMED, headquartered in Hamburg, Germany, with a US subsidiary in Kensington, MD, generates, characterizes and analyzes highly standardized biological samples from human cancer patients.
Founded in 2002, INDIVUMED has cooperation agreements with all major oncological hospitals in the Hamburg metropolitan area as well as with Georgetown University Medical Center in Washington D.C., USA.
INDIVUMED integrates a unique infrastructure of proprietary clinical and laboratory facilities with an outstanding biospecimen biobank of more than 10,000 patient-cases. Pharmaceutical and diagnostic companies as well as academic institutions around the world benefit from our highly standardized sample processing and analysis capabilities through a comprehensive service offering that provides customer a one-stop-solution for almost all kind of tissue based research. Service is including full pathology service, drug profiling applying primary tumor cultures, a comprehensive biobank portfolio and further research services.
INDIVUMED also pursues cancer biomarker discovery programs.
In September 2008 INDIVUMED founded the subsidiary INOSTICS GmbH together with researchers from Johns Hopkins University, Baltimore, Maryland. Inostics is also located in Hamburg, Germany. For more details see www.inostics.com.
How can drug companies and researchers battle cancer without high quality biosamples, meticulous data collection (with a robust IT backbone) and longterm follow-up of patients? Can community surgeons with high volume practices help?
